A Study to Evaluate the Efficacy and Safety of ZILRETTA in Subjects With Glenohumeral Osteoarthritis

Status: Recruiting
Location: See all (32) locations...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo Secondary Objective: * To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, immediate release (TCA-IR) and normal saline placebo * To assess the safety of ZILRETTA in subjects with glenohumeral OA relative to normal saline placebo and TCA-IR

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 80
Healthy Volunteers: f
View:

• Written informed consent has been obtained prior to initiating any study-specific procedures.

• Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions, including eDiary questionnaire completion requirements.

• Subjects 50 to 80 years of age, inclusive, on the day of consent.

• Body Mass Index (BMI) ≤40 kg/m2.

• Symptoms (including pain) associated with OA of the index shoulder for ≥3 months prior to Screening Visit (subject self-report is acceptable).

• Shoulder pain due to OA for \>15 days over the last month (as reported by the subject).

• Grade 2 or 3 OA in the index glenohumeral joint based on the Samilson-Prieto classification system as confirmed by X-ray (axillary view and true anterior-posterior view) taken at, or within 6 months of, the Screening Visit and read by the central reader.

• Average daily mean pain score ≥4.0 and ≤9.0 in index shoulder (0-10 numeric rating scale \[NRS\]) using the average daily ratings for at least 4 out of the 7 days prior to Baseline/Day 1.

• Average Shoulder Pain and Disability Index (SPADI) pain score ≥5.0 and ≤9.0 in index shoulder prior to Baseline/Day 1.

⁃ Willingness to abstain from use of protocol-specified restricted medications and therapies during the study.

⁃ Sexually active males or females of childbearing potential must agree to use a highly effective method of contraception throughout the duration of the study. Females of childbearing potential are defined as females who are not surgically sterile or postmenopausal (defined as 12 consecutive months with no menses without an alternative medical cause) as documented in medical history. Highly effective methods of contraception include abstinence; oral, injected, or implanted hormonal methods of contraception; intrauterine device or intrauterine system; condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; or monogamous intercourse with a partner who is surgically sterile (post-vasectomy, -hysterectomy, or -tubal ligation).

Locations
United States
Alabama
Alabama Orthopaedic Center- Research
RECRUITING
Vestavia Hills
Arizona
Onyx Clinical Research
RECRUITING
Surprise
Tucson Orthopaedic Institute (TOI) - East Office
RECRUITING
Tucson
California
Horizon Clinical Research
RECRUITING
La Mesa
Napa Pain Institute
RECRUITING
Napa
Stanford University - Sports Medicine Clinic
RECRUITING
Redwood City
Washington, D.c.
International Spine, Pain & Performance Center
RECRUITING
Washington D.c.
Florida
Orthopedic Center of Palm Beach City
COMPLETED
Atlantis
Baptist Health Orthopedic Care - Miami Gardens
RECRUITING
Miami
Infinite Clinical Research
RECRUITING
Miami
Gulfcoast Research Institute
RECRUITING
Sarasota
Clinical Research of West Florida
ACTIVE_NOT_RECRUITING
Tampa
Hospital for Special Services
RECRUITING
West Palm Beach
Idaho
Injury Care Research
RECRUITING
Boise
Kansas
Kansas City Bone & Joint Clinic - Overland Park
RECRUITING
Overland Park
Louisiana
Ochsner Sports Medicine Institute
RECRUITING
New Orleans
Massachusetts
New England Baptist Hospital
RECRUITING
Boston
Michigan
Oakland Medical Center
RECRUITING
Troy
Missouri
Sundance Clinical Research
RECRUITING
St Louis
North Carolina
West Clinical Research
RECRUITING
Morehead City
New York
New York-Presbyterian Queens
RECRUITING
Flushing
Ohio
University of Cincinnati
RECRUITING
Cincinnati
Ohio State University
RECRUITING
Columbus
Pennsylvania
University Orthopedics Center
RECRUITING
Altoona
Altoona Arthritis & Osteoporosis Center - Altoona Center for Clinical Research
RECRUITING
Duncansville
University Orthopedics Center (UOC) - State College
RECRUITING
State College
South Carolina
Medical University Health - West Ashley Medical Pavilion
RECRUITING
Charleston
Texas
Texas Orthopedic Specialists, PLLC
RECRUITING
Bedford
First Surgical Hospital
RECRUITING
Bellaire
El Paso Clinical Trials, LLC
RECRUITING
El Paso
Utah
Physicians Research Options
COMPLETED
Draper
Virginia
Spectrum Medical
RECRUITING
Danville
Contact Information
Primary
Jennifer Gordon
jennifer.gordon@pacira.com
973-451-4055
Time Frame
Start Date: 2024-02-05
Estimated Completion Date: 2025-08
Participants
Target number of participants: 250
Treatments
Experimental: ZILRETTA
100 subjects will receive 32 mg ZILRETTA
Active_comparator: TCA-IR
100 subjects will receive 40 mg TCA-IR
Placebo_comparator: Placebo
50 subjects will receive normal saline placebo
Related Therapeutic Areas
Sponsors
Leads: Pacira Pharmaceuticals, Inc

This content was sourced from clinicaltrials.gov